WUGEN

wugen-logo

Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
#SimilarOrganizations #People #Financial #Website #More

WUGEN

Social Links:

linkedin

Linkedin

Industry:
Biotechnology Therapeutics

Founded:
2018-01-01

Address:
St Louis, Missouri, United States

Country:
United States

Website Url:
http://www.wugen.com

Total Employee:
51+

Status:
Active

Total Funding:
172 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress


Similar Organizations

acrivon-therapeutics-logo

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

spero-therapeutics-logo

Spero Therapeutics

Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.


Current Advisors List

peter-kiener_image

Peter Kiener Board Member @ Wugen
Board_member

bosun-hau_image

Bosun Hau Board Member @ Wugen
Board_member

bali-muralidhar_image

Bali Muralidhar Board Member @ Wugen
Board_member

john-mckearn_image

John McKearn Board Member @ Wugen
Board_member

Current Employees Featured

ayman-kabakibi_image

Ayman Kabakibi
Ayman Kabakibi Chief Operating Officer, Executive Vice President of Research & Development @ Wugen
Chief Operating Officer, Executive Vice President of Research & Development
2021-01-01

john-mckearn_image

John McKearn
John McKearn CHIEF EXECUTIVE OFFICER AND PRESIDENT @ Wugen
CHIEF EXECUTIVE OFFICER AND PRESIDENT

jan-davidson_image

Jan Davidson
Jan Davidson Chief Medical Officer @ Wugen
Chief Medical Officer
2021-02-01

not_available_image

Matthew Cooper
Matthew Cooper Co-Founder and Chief Scientific Officer @ Wugen
Co-Founder and Chief Scientific Officer
2018-08-01

Founder


not_available_image

Matthew Cooper

Investors List

intermediate-capital-group_image

Intermediate Capital Group

Intermediate Capital Group investment in Series B - Wugen

alexandria-venture-investments_image

Alexandria Venture Investments

Alexandria Venture Investments investment in Series B - Wugen

lightchain_image

Lightchain

Lightchain investment in Series B - Wugen

aisling-capital_image

Aisling Capital

Aisling Capital investment in Series B - Wugen

fidelity-management-and-research-company_image

Fidelity Management and Research Company

Fidelity Management and Research Company investment in Series B - Wugen

falcon-edge-capital-2_image

Alpha Wave Global

Alpha Wave Global investment in Series B - Wugen

lyzz-capital_image

LYZZ Capital

LYZZ Capital investment in Series B - Wugen

abingworth-management_image

Abingworth

Abingworth investment in Series B - Wugen

tybourne_image

Tybourne Capital Management

Tybourne Capital Management investment in Series B - Wugen

velosity-capital_image

Velosity Capital

Velosity Capital investment in Series B - Wugen

Official Site Inspections

http://www.wugen.com Semrush global rank: 9.54 M Semrush visits lastest month: 141

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Wugen" on Search Engine

dfkcompany.com © 2022. All rights reserved